Skip to main content
Year archive

Nykode Therapeutics ASA — 2022 filings

All 96 regulatory filings released by Nykode Therapeutics ASA (NYKD) in 2022, sourced directly from the official regulator.

96 Filings
2022 Period
2022 filings (96)
Filing Released Lang
Financial calendar
Report Publication Announcement
2022-12-30 English
Nykode Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Report Publication Announcement
2022-12-23 English
Nykode Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Investor Presentation
2022-12-23 English
Share capital increase from exercise of warrants
Share Issue/Capital Change
2022-12-22 English
Registration of new share capital
Share Issue/Capital Change
2022-12-20 English
Nykode announces expanded clinical development plan for its lead cancer vaccine VB10.16 in HPV16-positive cancers
Regulatory Filings
2022-12-20 English
Nykode announces expanded clinical development plan for its lead cancer vaccine VB10.16 in HPV16-positive cancers
Share Issue/Capital Change
2022-12-20 English
Nykode Therapeutics and Richter-Helm BioLogics Announce Strategic Manufacturing Partnership
Regulatory Filings
2022-12-19 English
Nykode Therapeutics and Richter-Helm BioLogics Announce Strategic Manufacturing Partnership
Regulatory Filings
2022-12-19 English
Exercise of warrants by primary insider, transactions by a primary insider and a close associate, and disclosure of large shareholding
Director's Dealing
2022-12-18 English
Exercise of warrants by primary insider, transactions by a primary insider and a close associate, and disclosure of large shareholding
Major Shareholding Notification
2022-12-18 English
Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination With KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive Head and Neck Cancer
M&A Activity
2022-12-06 English
Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination With KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive Head and Neck Cancer
Regulatory Filings
2022-12-06 English
Nykode Therapeutics - Quarterly report 3Q 2022
Interim / Quarterly Report Q3 2022
2022-11-23 English
Nykode Therapeutics - Quarterly report 3Q 2022
Report Publication Announcement 9M 2022
2022-11-23 English
Nykode Therapeutics to announce financial results for the third quarter 2022 and host webcast presentation on November 23, 2022
Report Publication Announcement
2022-11-16 English
Nykode Therapeutics presents additional efficacy analysis in Phase 2 study of VB10.16 in combination with atezolizumab in advanced cervical cancer
Earnings Release FY 2022
2022-11-07 English
Nykode Therapeutics presents additional efficacy analysis in Phase 2 study of VB10.16 in combination with atezolizumab in advanced cervical cancer
Regulatory Filings
2022-11-07 English
Nykode Therapeutics to present at two upcoming investor conferences in November
Report Publication Announcement
2022-11-07 English
Nykode Therapeutics to present at two upcoming investor conferences in November
Regulatory Filings
2022-11-07 English
Nykode Therapeutics Announces Presentation of Positive Immunogenicity Results from Phase 1/2a Study of VB10.NEO, an Individualized Therapeutic Cancer Vaccine, at the Neoantigen-Based Therapies Summit
Earnings Release Q4 2022
2022-10-26 English
Nykode Therapeutics Announces Presentation of Positive Immunogenicity Results from Phase 1/2a Study of VB10.NEO, an Individualized Therapeutic Cancer Vaccine, at the Neoantigen-Based Therapies Summit
Earnings Release Q4 2022
2022-10-26 English
Mandatory notification of intra group transfer of shares by primary insider’s related party
Director's Dealing
2022-10-24 English
Mandatory notification of intra group transfer of shares by primary insider’s related party
Director's Dealing
2022-10-24 English
Nykode Therapeutics Announces Positive Results from the Phase 1/2 Open Label, Dose Escalation Trial of its T Cell Focused SARS-CoV-2 Vaccine Candidate
Earnings Release Q3 2022
2022-09-27 English
Nykode Therapeutics Announces Positive Results from the Phase 1/2 Open Label, Dose Escalation Trial of its T Cell Focused SARS-CoV-2 Vaccine Candidate
Regulatory Filings
2022-09-27 English
Nykode Therapeutics to present at H.C. Wainwright 24th Annual Global Investment Conference
Regulatory Filings
2022-09-09 English
Nykode Therapeutics to present at H.C. Wainwright 24th Annual Global Investment Conference
Report Publication Announcement
2022-09-09 English
Nykode Therapeutics to be included in the Oslo Børs Benchmark Index (OSEBX) and the Oslo Børs Mutual Fund Index (OSEFX)
Regulatory Filings
2022-09-08 English
Nykode Therapeutics ASA - Mandatory notification for close associate of primary insider
Director's Dealing
2022-08-26 English
Nykode Therapeutics ASA - Mandatory notification for close associate of primary insider
Major Shareholding Notification
2022-08-26 English
Nykode Therapeutics - Quarterly report 2Q 2022
Interim / Quarterly Report Q2 2022
2022-08-24 English
Nykode Therapeutics - Quarterly report 2Q 2022
Report Publication Announcement H1 2022
2022-08-24 English
Nykode Therapeutics to announce financial results for the first half of 2022 and host webcast presentation on August 24, 2022
Report Publication Announcement
2022-08-22 English
Nykode Therapeutics to announce financial results for the first half of 2022 and host webcast presentation on August 24, 2022
Report Publication Announcement
2022-08-22 English
Grant of Share Options
Director's Dealing
2022-07-04 English
Grant of Share Options
Remuneration Information
2022-07-04 English
Nykode Therapeutics uplisted to the main list of the Oslo Stock Exchange
Regulatory Filings
2022-06-16 Norwegian
Nykode Therapeutics uplisted to the main list of the Oslo Stock Exchange
Regulatory Filings
2022-06-16 English
Nykode Therapeutics - approval and publication of prospectus and admission to trading on the Oslo Stock Exchange’s main list
Report Publication Announcement
2022-06-15 Norwegian
Nykode Therapeutics - approval and publication of prospectus and admission to trading on the Oslo Stock Exchange’s main list
Report Publication Announcement
2022-06-15 English
Oslo Børs - Decision on admission to trading – Nykode Therapeutics ASA
Regulatory Filings
2022-06-13 English
Nykode Therapeutics appoints Klaus Edvardsen as Chief Development Officer
Board/Management Information
2022-06-13 English
Nykode Therapeutics appoints Klaus Edvardsen as Chief Development Officer
Board/Management Information
2022-06-13 English
Application for transfer of shares admitted to trading on Euronext Growth to Oslo Børs
Regulatory Filings
2022-06-08 English
Nykode Therapeutics ASA - Conversion to public limited liability company registered
Regulatory Filings
2022-06-02 English
Nykode Therapeutics ASA - Conversion to public limited liability company registered
Regulatory Filings
2022-06-02 English
Nykode Therapeutics to Present at Jefferies Healthcare Conference
Report Publication Announcement
2022-06-01 English
Nykode Therapeutics to Present at Jefferies Healthcare Conference
Regulatory Filings
2022-06-01 English
Mandatory notification of acquisition of shares by primary insider
Director's Dealing
2022-05-18 English
Mandatory notification of acquisition of shares by primary insider
Director's Dealing
2022-05-18 English
Grant of share options
Director's Dealing
2022-05-16 English
Grant of share options
Share Issue/Capital Change
2022-05-16 English
Nykode Therapeutics - Quarterly report Q1 2022
Interim / Quarterly Report Q1 2022
2022-05-16 English
Nykode Therapeutics - Quarterly report Q1 2022
Report Publication Announcement
2022-05-16 English
Nykode Therapeutics AS - Minutes of Annual General Meeting
AGM Information
2022-05-12 Norwegian
Nykode Therapeutics AS - Minutes of Annual General Meeting
AGM Information
2022-05-12 Norwegian
Financial calendar
Report Publication Announcement
2022-05-11 English
Nykode Therapeutics announces positive interim results from its Phase 2 trial with VB10.16 in combination with immune checkpoint inhibitor atezolizumab in advanced cervical cancer
Regulatory Filings
2022-05-09 English
Nykode Therapeutics announces positive interim results from its Phase 2 trial with VB10.16 in combination with immune checkpoint inhibitor atezolizumab in advanced cervical cancer
Earnings Release Q1 2022
2022-05-09 English
Nykode Therapeutics – Invitation to Capital Markets Day in Oslo on May 12, 2022
Report Publication Announcement
2022-05-06 Norwegian
Nykode Therapeutics – Invitation to Capital Markets Day in Oslo on May 12, 2022
Report Publication Announcement
2022-05-06 English
Nykode Therapeutics AS - Notice of Annual General Meeting
Capital/Financing Update
2022-05-05 Norwegian
Nykode Therapeutics AS - Notice of Annual General Meeting
AGM Information
2022-05-05 English
Nykode Therapeutics AS - Notice of Annual General Meeting
Annual Report FY 2021
2022-05-05 English
Nykode Therapeutics AS - Notice of Annual General Meeting
AGM Information
2022-05-05 Norwegian
Nykode Therapeutics AS - Notice of Annual General Meeting
AGM Information
2022-05-05 Norwegian
Nykode Therapeutics AS - Notice of Annual General Meeting
AGM Information
2022-05-05 English
Nykode Therapeutics to host Capital Markets Day
Report Publication Announcement
2022-04-19 English
Nykode Therapeutics to host Capital Markets Day
Investor Presentation
2022-04-19 English
Nykode Therapeutics to present at Kempen Life Sciences Conference
Regulatory Filings
2022-04-19 English
Nykode Therapeutics to present at Kempen Life Sciences Conference
Investor Presentation
2022-04-19 English
Nykode Therapeutics announces presentation of preclinical data from its second generation Vaccibody vaccine technology at 2022 American Association for Cancer Research (AACR) Annual Meeting
Regulatory Filings
2022-04-08 English
Nykode Therapeutics announces presentation of preclinical data from its second generation Vaccibody vaccine technology at 2022 American Association for Cancer Research (AACR) Annual Meeting
Investor Presentation
2022-04-08 English
Registration of new share capital
Share Issue/Capital Change
2022-04-08 English
Nykode Therapeutics - full year 2021 financial results and corporate presentation
Investor Presentation
2022-04-01 English
Nykode Therapeutics - full year 2021 financial results and corporate presentation
Earnings Release FY 2021
2022-04-01 English
Nykode Therapeutics - full year 2021 financial results and corporate presentation
Investor Presentation
2022-04-01 English
Mandatory notification of exercise of warrants and sale of shares to primary insider’s related party
Director's Dealing
2022-03-31 English
Mandatory notification of exercise of warrants and sale of shares to primary insider’s related party
Director's Dealing
2022-03-31 English
Nykode Therapeutics reports full year 2021 financial results
Annual Report FY 2021
2022-03-31 English
Nykode Therapeutics reports full year 2021 financial results
Earnings Release FY 2021
2022-03-31 English
Nykode Therapeutics reports full year 2021 financial results
Earnings Release FY 2021
2022-03-31 English
Nykode to announce full year 2021 financial results on March 31, 2022 and host webcast presentation on April 1, 2022
Report Publication Announcement
2022-03-28 English
Nykode to announce full year 2021 financial results on March 31, 2022 and host webcast presentation on April 1, 2022
Report Publication Announcement
2022-03-28 English
Nykode Therapeutics to Present at 2022 American Association for Cancer Research (AACR) Annual Meeting
Report Publication Announcement
2022-03-08 English
Nykode Therapeutics to Present at 2022 American Association for Cancer Research (AACR) Annual Meeting
Report Publication Announcement
2022-03-08 English
Share capital increase from exercise of warrants
Share Issue/Capital Change
2022-03-01 English
Mandatory notification of acquisition of shares by primary insider
Director's Dealing
2022-02-22 English
Mandatory notification of acquisition of shares by primary insider
Director's Dealing
2022-02-22 English
Mandatory notification of exercise of warrants
Director's Dealing
2022-02-15 English
Mandatory notification of exercise of warrants
Share Issue/Capital Change
2022-02-15 English
Nykode Therapeutics to Present at SVB Leerink 2022 Global Healthcare Conference
Report Publication Announcement
2022-02-14 English
Nykode Therapeutics to Present at SVB Leerink 2022 Global Healthcare Conference
Report Publication Announcement
2022-02-14 English
Nykode Therapeutics announces completion of patient enrollment in its Phase 2 trial of VB10.16 in combination with atezolizumab for the treatment of advanced cervical cancer
Regulatory Filings
2022-02-11 English
Nykode Therapeutics announces completion of patient enrollment in its Phase 2 trial of VB10.16 in combination with atezolizumab for the treatment of advanced cervical cancer
Regulatory Filings
2022-02-11 English